1 Aside from acting as a weight-loss agent and treatment for T2D, semaglutide has showed effectiveness in treating a variety of conditions
For continuation versus noncontinuation, the weighted prevalence ratios were 1.29 (95 percent confidence interval, 0.82 to 2.06), 1.08 (95 percent confidence interval, 0.84 to 1.40), and 1.21 (95 percent confidence interval, 0.83 to 1.82) for small for gestational age, large for gestational age, and MCM, respectively."Accumulated evidence provides some reassurance about risk for malformations after inadvertent exposure in women who become pregnant while using GLP-1 RAs," the authors write.Abstract/Full Text (subscription or payment may be required).Sign up for our weekly HealthDay newsletter
As the public may recall, Hims & Hers began selling various Eli Lilly drugs on their platform last monthboth branded forms of tirzepatideincluding Zepbound, a GLP-1 receptor agonist approved by the FDA for weight loss, and Mounjaro, which is not approved for weight loss but for the treatment of type 2 diabetes
These look like print versions of what you might see on a tablet